Last reviewed · How we verify

tamoxifen citrate (Tamoxifen) — Competitive Intelligence Brief

tamoxifen citrate (Tamoxifen) (tamoxifen citrate (Tamoxifen)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM). Area: Oncology.

marketed Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

tamoxifen citrate (Tamoxifen) (tamoxifen citrate (Tamoxifen)) — H. Lee Moffitt Cancer Center and Research Institute. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
tamoxifen citrate (Tamoxifen) TARGET tamoxifen citrate (Tamoxifen) H. Lee Moffitt Cancer Center and Research Institute marketed Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα)
teriparatide and raloxifene teriparatide and raloxifene Medical University of Vienna marketed Combination therapy: PTH analog and selective estrogen receptor modulator (SERM) PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)
E2Nomac E2Nomac Sydney Centre for Reproductive Health Research marketed Selective Estrogen Receptor Modulator (SERM) Estrogen receptor (ER-α/ER-β)
Tamoxifen Oral Tablet Tamoxifen Oral Tablet Samsung Medical Center marketed Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα)
Tamoxifen (open label) Tamoxifen (open label) Oregon Health and Science University marketed Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα)
Low Dose Clomiphencitrat Low Dose Clomiphencitrat University Hospital, Basel, Switzerland marketed Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β)
fenofibrate and tibolone fenofibrate and tibolone Keogh Institute for Medical Research marketed Fibrate + Selective Estrogen Receptor Modulator (SERM) PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) class)

  1. University Hospital, Basel, Switzerland · 2 drugs in this class
  2. AstraZeneca · 2 drugs in this class
  3. Estetra · 1 drug in this class
  4. Fundació Privada Eugin · 1 drug in this class
  5. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
  6. National Taiwan University Hospital · 1 drug in this class
  7. Oregon Health and Science University · 1 drug in this class
  8. Samsung Medical Center · 1 drug in this class
  9. Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class
  10. Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tamoxifen citrate (Tamoxifen) — Competitive Intelligence Brief. https://druglandscape.com/ci/tamoxifen-citrate-tamoxifen. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: